Keyphrases
Adverse Events
20%
Anti-programmed Death 1
100%
Biochemical Relapse
20%
Chronic Lymphocytic Leukemia
100%
Clinical Effect
20%
Consolidating Treatment
20%
Early Disease Progression
20%
End of Treatment
20%
Favorable Outcome
20%
Follow-up Time
40%
High Tumor Burden
20%
Immunogenicity
20%
Immunoglobulin Heavy Chain
100%
Immunological Control
20%
International Workshop
20%
Leukemia Patients
100%
Median Time
40%
Monotherapy
20%
Novel Targeted Therapy
20%
Peripheral Lymphocyte Count
20%
Preventive Strategies
20%
Previously Untreated
20%
Programmed Death-ligand 1 (PD-L1)
100%
Randomized Setting
20%
Response Criteria
20%
Specific Immune Response
20%
Stable Disease
40%
Therapeutic Vaccination
100%
Therapeutic Vaccine
20%
Time to First Treatment
40%
Treatment Needs
20%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
20%
Cancer Vaccine
20%
Chronic Lymphatic Leukemia
100%
Disease
60%
Disease Exacerbation
20%
Immunogenicity
20%
Immunoglobulin Heavy Chain
100%
Monotherapy
20%
Neoplasm
20%
Programmed Death 1 Ligand 1
100%
Remission
20%
Vaccination Policy
100%
Immunology and Microbiology
Cancer Vaccine
20%
Immune Response
20%
Immunogenicity
20%
Immunoglobulin Heavy Chain
100%
Lymphocyte Count
20%
Programmed Death 1 Ligand 1
100%
Programmed Death-Ligand 1
100%
Tumor Volume
20%
Vaccination Policy
100%
Vaccine Efficacy
100%